Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any inflammatory bowel disease in which the cause of the disease is a mutation in the IL10RA gene.
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 7:21 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Features include always present findings: Hematochezia, Oral ulcer, Enterocolitis, and Crohn's disease and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Digestive system | 1 | Colitis |
Growth and development | 1 | Growth delay |
Age of onset: infancy, newborn period.
IL10RA encodes interleukin 10 receptor subunit alpha (578 aa). Cell surface receptor for the cytokine IL10 that participates in IL10-mediated anti-inflammatory functions, limiting excessive tissue disruption caused by inflammation. Highest expression in Spleen (149.9 TPM) and Whole Blood (69.4 TPM).
Inflammatory bowel disease 28 is caused by mutations in the IL10RA gene on chromosome 11.
The IL10RA protein participates in Crizotinib-driven IL10RA gene expression in NPM1-ALK pathway.
IL10RA is classified as a druggable target (Clinically Actionable, Druggable Genome, and Kinase categories) with score 17.4.
Genetic testing for IL10RA is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 9 always present features.
No clinical trials have been registered for inflammatory bowel disease 28.
25 publications have been identified in PubMed for inflammatory bowel disease 28. Research spans Basic Science / Preclinical (32%), Epidemiology / Natural History (24%), and Case Report / Case Series (16%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 8 | 32% |
Disease patterns and progression | 6 | 24% |
Patient case studies | 4 | 16% |
Research summaries | 3 | 12% |
Clinical study results | 3 | 12% |
New treatment approaches | 1 | 4% |
Nguyen MC (2026). [PMID: 42194192](https://pubmed.ncbi.nlm.nih.gov/42194192/). *Children (Basel)*. [Epidemiology / Natural History]
Qiu R (2026). [PMID: 41606474](https://pubmed.ncbi.nlm.nih.gov/41606474/). *BMC gastroenterology*. [Case Report / Case Series]
Shojaei Jeshvaghani Z (2026). [PMID: 41273131](https://pubmed.ncbi.nlm.nih.gov/41273131/). *Inflammatory bowel diseases*. [Basic Science / Preclinical]
Wang CR (2026). [PMID: 41846353](https://pubmed.ncbi.nlm.nih.gov/41846353/). *Zhongguo shi yan xue ye xue za zhi*. [Clinical Trial Publication]
Xiao J (2026). [PMID: 41888292](https://pubmed.ncbi.nlm.nih.gov/41888292/). *Clinical reviews in allergy & immunology*. [Review / Meta-Analysis]
Cetinoglu S (2026). [PMID: 41592969](https://pubmed.ncbi.nlm.nih.gov/41592969/). *Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology*. [Epidemiology / Natural History]
Abhari AP (2026). [PMID: 41540376](https://pubmed.ncbi.nlm.nih.gov/41540376/). *BMC gastroenterology*. [Review / Meta-Analysis]
Gong Y (2026). [PMID: 41840589](https://pubmed.ncbi.nlm.nih.gov/41840589/). *BMC pediatrics*. [Epidemiology / Natural History]
Ren A (2026). [PMID: 42064076](https://pubmed.ncbi.nlm.nih.gov/42064076/). *Front Immunol*. [Case Report / Case Series]
Ito T (2026). [PMID: 42120015](https://pubmed.ncbi.nlm.nih.gov/42120015/). *Int Immunol*. [Basic Science / Preclinical]